PMID- 11050634
OWN - NLM
STAT- MEDLINE
DCOM- 20001214
LR  - 20220318
IS  - 1053-1807 (Print)
IS  - 1053-1807 (Linking)
VI  - 12
IP  - 5
DP  - 2000 Nov
TI  - Staging of rectal cancer by double-contrast MR imaging using the rectally 
      administered superparamagnetic iron oxide contrast agent ferristene and IV 
      gadodiamide injection: results of a multicenter phase II trial.
PG  - 651-60
AB  - The aim of this study was to assess the accuracy of double-contrast magnetic 
      resonance imaging (MRI) with rectal application of the superparamagnetic iron 
      oxide contrast agent (SPIO) ferristene and IV gadodiamide for preoperative 
      staging of rectal cancer. In a randomized phase II dose-ranging trial, 113 
      patients were studied preoperatively with one of four different formulations of 
      ferristene (Abdoscan) as an enema before MRI. T1-weighted spin-echo (T1w SE) and 
      T2w turbo spin-echo (TSE) single-contrast images were obtained as well as T1w SE 
      and gradient-echo (GRE) double-contrast images after IV gadodiamide injection 
      (Omniscan). Images were assessed qualitatively, and TNM tumor stage was compared 
      with histopathology. High-viscosity ferristene formulations were superior to 
      low-viscosity formulations in tumor staging (accuracy 90% vs 74%, P < 0.01). 
      There was no significant difference between high and low iron content ferristene. 
      MRI had a sensitivity of 97%, specificity of 50%, and accuracy of 82% for staging 
      of rectal carcinoma higher than T2 stage. At receiver operator characteristic 
      (ROC) analysis, MR differentiation between T1/T2 and T3/T4 tumor stages yielded a 
      ROC index of 0.848. Double-contrast MRI is an accurate method for preoperative 
      staging of rectal cancer.
FAU - Maier, A G
AU  - Maier AG
AD  - Department of Radiology, University of Vienna, 1090 Vienna, Austria. 
      andrea.maier@univie.ac.at
FAU - Kersting-Sommerhoff, B
AU  - Kersting-Sommerhoff B
FAU - Reeders, J W
AU  - Reeders JW
FAU - Judmaier, W
AU  - Judmaier W
FAU - Schima, W
AU  - Schima W
FAU - Annweiler, A A
AU  - Annweiler AA
FAU - Meusel, M
AU  - Meusel M
FAU - Wallengren, N O
AU  - Wallengren NO
LA  - eng
PT  - Clinical Trial
PT  - Clinical Trial, Phase II
PT  - Comparative Study
PT  - Journal Article
PT  - Multicenter Study
PT  - Randomized Controlled Trial
PL  - United States
TA  - J Magn Reson Imaging
JT  - Journal of magnetic resonance imaging : JMRI
JID - 9105850
RN  - 0 (Contrast Media)
RN  - 0 (Ferric Compounds)
RN  - 155773-56-1 (ferristene)
RN  - 84F6U3J2R6 (gadodiamide)
RN  - K2I13DR72L (Gadolinium DTPA)
SB  - IM
EIN - J Magn Reson Imaging 2001 Mar;13(3):481
MH  - Adenocarcinoma/diagnosis/*pathology/surgery
MH  - Administration, Rectal
MH  - Adult
MH  - Aged
MH  - Biopsy, Needle
MH  - Chi-Square Distribution
MH  - *Contrast Media
MH  - Dose-Response Relationship, Drug
MH  - Female
MH  - *Ferric Compounds
MH  - *Gadolinium DTPA
MH  - Humans
MH  - Image Processing, Computer-Assisted
MH  - Injections, Intravenous
MH  - Magnetic Resonance Imaging/*methods
MH  - Male
MH  - Middle Aged
MH  - Neoplasm Staging/methods
MH  - Preoperative Care
MH  - Probability
MH  - ROC Curve
MH  - Rectal Neoplasms/diagnosis/*pathology/surgery
MH  - Sensitivity and Specificity
EDAT- 2000/10/26 11:00
MHDA- 2001/02/28 10:01
CRDT- 2000/10/26 11:00
PHST- 2000/10/26 11:00 [pubmed]
PHST- 2001/02/28 10:01 [medline]
PHST- 2000/10/26 11:00 [entrez]
AID - 10.1002/1522-2586(200011)12:5<651::AID-JMRI1>3.0.CO;2-R [pii]
AID - 10.1002/1522-2586(200011)12:5<651::aid-jmri1>3.0.co;2-r [doi]
PST - ppublish
SO  - J Magn Reson Imaging. 2000 Nov;12(5):651-60. doi: 
      10.1002/1522-2586(200011)12:5<651::aid-jmri1>3.0.co;2-r.